

Gambro receives US 510(k) approval for new dialyzer for treatment of renal failure

Stockholm, Sweden, July 8, 2003 – Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that Gambro Renal Products in the United States has received FDA clearance of the 510(k) Notification for the Polyflux® LR Hemodialyzer. This is the newest member of its Polyflux hemodialyzer product line, used for the treatment of chronic and acute renal failure. The Polyflux LR may be reprocessed for reuse on the same patient.

“Responding to our customers’ demand for a high efficiency, low flux, reuse dialyzer, Gambro Renal Products continues to provide exceptional medical devices for renal failure patients”, said Len Braganza, President Gambro Renal Products, U.S. “We are extremely excited about the newest member of the Polyflux family. The Polyflux LR dialyzer, not only extends a legendary line of Gambro dialyzer products, but completes the variety of Gambro dialyzers offered to healthcare professionals for all hemodialysis patients.”

Polyflux LR features Gambro’s exclusive membrane technology of a three-layer microstructure which offers maximum permeability for uremic toxins removal and a protective barrier against the risk of losing proteins or infusing endotoxins. The Polyflux membrane offers the distinct attributes of minimal thrombogenic events, a stable sieving coefficient, predictable dialysis dose (Kt/V), and outstanding biocompatibility with low complement activation. Additionally, the membrane brings about easy priming, negligible protein adhesion, and excellent rinse-back.

For further information please contact:

Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 33,
+46-70-513 65 33

Pia Irell, Investor Relations Director, Corporate Finance, tel. +46-8-613 65 91, +46-70-513 65 91
Kevin Smith, President Gambro Inc., Investor Relations US, tel. +1-303 231 4750

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with more than 54,300 patients in more than 700 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT is the market leader in separation and handling of blood components. The group, with 2002 revenues of approximately SEK 27.6 billion (USD 2.7 billion), has 20,900 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Jakobsgatan 6, PO Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com